Jonathan Young, Chief Operating Officer at Akero Therapeutics, Inc. (AKRO), sold 25,000 shares at $47.72 ($1.2M) on 2025-08-12, disclosed to the SEC on 2025-08-13.
Scheduled sale ($1.2M) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $47.72 | 11,151 | $532K | 44.5% |
| 2 | $47.72 | 11,151 | $532K | 44.5% |
| 3 | $48.32 | 1,349 | $65K | 5.5% |
| 4 | $48.32 | 1,349 | $65K | 5.5% |
| Total | $47.78 avg | 25,000 | $1.2M | 100% |
| Filing → |
| AKRO | SELL | 2025-09-04 | $705K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $159K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $269K | — | Filing → |